Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, ... Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; NMRA-266 for the treatment of schizophrenia and other neuropsychiatric disorders; NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Mehr anzeigen
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.02 | -1.4598540146 | 1.37 | 1.5394 | 1.26 | 1229907 | 1.4427888 | CS |
| 4 | -0.4 | -22.8571428571 | 1.75 | 1.83 | 1.26 | 1435845 | 1.61719564 | CS |
| 12 | -9.47 | -87.5231053604 | 10.82 | 11.57 | 1.26 | 3408975 | 2.48908791 | CS |
| 26 | -9.83 | -87.9248658318 | 11.18 | 17.1874 | 1.26 | 2123715 | 5.45297009 | CS |
| 52 | -16.6 | -92.4791086351 | 17.95 | 18.61 | 1.26 | 1374370 | 6.87245371 | CS |
| 156 | -15.15 | -91.8181818182 | 16.5 | 21 | 1.26 | 1027921 | 7.57957877 | CS |
| 260 | -15.15 | -91.8181818182 | 16.5 | 21 | 1.26 | 1027921 | 7.57957877 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
